BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 27013382)

  • 1. Comparison of two pancreatic enzyme products for exocrine insufficiency in patients with cystic fibrosis.
    Taylor CJ; Thieroff-Ekerdt R; Shiff S; Magnus L; Fleming R; Gommoll C
    J Cyst Fibros; 2016 Sep; 15(5):675-80. PubMed ID: 27013382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.
    Graff GR; Maguiness K; McNamara J; Morton R; Boyd D; Beckmann K; Bennett D
    Clin Ther; 2010 Jan; 32(1):89-103. PubMed ID: 20171415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis.
    Trapnell BC; Maguiness K; Graff GR; Boyd D; Beckmann K; Caras S
    J Cyst Fibros; 2009 Dec; 8(6):370-7. PubMed ID: 19815466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a novel pancreatic enzyme product, EUR-1008 (Zenpep), in patients with exocrine pancreatic insufficiency due to chronic pancreatitis.
    Toskes PP; Secci A; Thieroff-Ekerdt R;
    Pancreas; 2011 Apr; 40(3):376-82. PubMed ID: 21343835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT.
    Van de Vijver E; Desager K; Mulberg AE; Staelens S; Verkade HJ; Bodewes FA; Malfroot A; Hauser B; Sinaasappel M; Van Biervliet S; Behm M; Pelckmans P; Callens D; Veereman-Wauters G
    J Pediatr Gastroenterol Nutr; 2011 Jul; 53(1):61-4. PubMed ID: 21694537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.
    Graff GR; McNamara J; Royall J; Caras S; Forssmann K
    Clin Drug Investig; 2010; 30(6):351-64. PubMed ID: 20441244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term experience with ZENPEP in infants with exocrine pancreatic insufficiency associated with cystic fibrosis.
    Wooldridge JL; Schaeffer D; Jacobs D; Thieroff-Ekerdt R
    J Pediatr Gastroenterol Nutr; 2014 Nov; 59(5):612-5. PubMed ID: 25050848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency.
    Wooldridge JL; Heubi JE; Amaro-Galvez R; Boas SR; Blake KV; Nasr SZ; Chatfield B; McColley SA; Woo MS; Hardy KA; Kravitz RM; Straforini C; Anelli M; Lee C
    J Cyst Fibros; 2009 Dec; 8(6):405-17. PubMed ID: 19683970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency.
    Stern RC; Eisenberg JD; Wagener JS; Ahrens R; Rock M; doPico G; Orenstein DM
    Am J Gastroenterol; 2000 Aug; 95(8):1932-8. PubMed ID: 10950038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis.
    Trapnell BC; Strausbaugh SD; Woo MS; Tong SY; Silber SA; Mulberg AE; Leitz G
    J Cyst Fibros; 2011 Sep; 10(5):350-6. PubMed ID: 21632288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.
    Kuhn RJ; Gelrud A; Munck A; Caras S
    Adv Ther; 2010 Dec; 27(12):895-916. PubMed ID: 21086085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of stool collections to measure efficacy of PERT in subjects with exocrine pancreatic insufficiency.
    Caras S; Boyd D; Zipfel L; Sander-Struckmeier S
    J Pediatr Gastroenterol Nutr; 2011 Dec; 53(6):634-40. PubMed ID: 21681115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary report of the (13)C-mixed triglyceride breath test to assess timing of pancreatic enzyme replacement therapy in children with cystic fibrosis.
    van der Haak N; Boase J; Davidson G; Butler R; Miller M; Kaambwa B; Kritas S
    J Cyst Fibros; 2016 Sep; 15(5):669-74. PubMed ID: 27102891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of a Novel Microbial Lipase in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis: A Randomized Controlled Clinical Trial.
    Heubi JE; Schaeffer D; Ahrens RC; Sollo N; Strausbaugh S; Graff G; Jain R; Witte S; Forssmann K
    J Pediatr; 2016 Sep; 176():156-161.e1. PubMed ID: 27297209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Not Available].
    Lenglinger J; Hädrich M
    Ther Umsch; 2016 Nov; 73(9):500-504. PubMed ID: 27805488
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study.
    Colombo C; Fredella C; Russo MC; Faelli N; Motta V; Valmarana L; Longo L; D'Orazio C
    Pancreas; 2009 Aug; 38(6):693-9. PubMed ID: 19531972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo-controlled study.
    Thorat V; Reddy N; Bhatia S; Bapaye A; Rajkumar JS; Kini DD; Kalla MM; Ramesh H
    Aliment Pharmacol Ther; 2012 Sep; 36(5):426-36. PubMed ID: 22762290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine Pancreatic Insufficiency and a Medical History of Diabetes Mellitus.
    Whitcomb DC; Bodhani A; Beckmann K; Sander-Struckmeier S; Liu S; Fuldeore M; Pollack PF; Khurmi RP
    Pancreas; 2016; 45(5):679-86. PubMed ID: 26495784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dependence of PERT endpoint on endogenous lipase activity.
    Gao WY; Mulberg AE
    Pancreas; 2014 Nov; 43(8):1232-8. PubMed ID: 25102439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the gastrointestinal bioavailability of a pancreatic extract product (Zenpep) in chronic pancreatitis patients with exocrine pancreatic insufficiency.
    Lieb JG; Patel D; Karnik N; Toskes PP
    Pancreatology; 2020 Sep; 20(6):1092-1102. PubMed ID: 32800653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.